Imaging Plaque Inflammation in Higher-Risk Patients: What Do We Know and What Are We Looking For?

被引:0
|
作者
Ishai A. [1 ]
Tawakol A. [1 ,2 ]
机构
[1] Cardiac MR PET CT Program, Department of Imaging, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
[2] Cardiology Division, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
关键词
Atherosclerosis; FDG-PET; Inflammation;
D O I
10.1007/s12170-015-0459-0
中图分类号
学科分类号
摘要
Atherosclerosis is a chronic inflammatory condition complicating cholesterol accumulation within the artery wall. Inflammation is believed to play an important role in the formation, progression, and ultimately the rupture of atherosclerotic plaques (the principle event leading to most myocardial infarctions and strokes). An enhanced understanding of the inflammatory process within the atheroma may therefore facilitate risk stratification and treatment strategies. Molecular imaging techniques such as PET/CT have the ability to quantify arterial inflammation and assess the high-risk features of atheromas thus may be useful for identifying patients who are at higher risk for an atherothrombotic event. In this review, we focus on the potential of FDG-PET/CT as a tool to measure arterial inflammation, enhance risk stratification, and to evaluate novel therapies directed against atherosclerotic disease. Additionally, this review will provide a discussion on current challenges as well as future directions. © 2015, Springer Science+Business Media New York.
引用
收藏
页码:1 / 8
页数:7
相关论文
共 50 条
  • [21] We do not know what we do not know
    Spaeth, GL
    OPHTHALMIC SURGERY AND LASERS, 1999, 30 (05): : 337 - 340
  • [22] How Do We "Know" What We "Know?" And Change What We "Know?"
    Fosshage, James L.
    PSYCHOANALYTIC DIALOGUES, 2011, 21 (01) : 55 - 74
  • [23] Do we know what we test and do we test what we want to know?
    Klugkist, Irene
    van Wesel, Floryt
    Bullens, Jessie
    INTERNATIONAL JOURNAL OF BEHAVIORAL DEVELOPMENT, 2011, 35 (06) : 550 - 560
  • [24] Voiding Dysfunction in Transgender Patients: What We Know and What We Do Not Know
    Gonzalez, Gabriela
    Anger, Jennifer T.
    CURRENT UROLOGY REPORTS, 2025, 26 (01)
  • [25] The risk of viral transmission in feed: What do we know, what do we do?
    Dee, Scott A.
    Niederwerder, Megan C.
    Patterson, Gil
    Cochrane, Roger
    Jones, Cassie
    Diel, Diego
    Brockhoff, Egan
    Nelson, Eric
    Spronk, Gordon
    Sundberg, Paul
    TRANSBOUNDARY AND EMERGING DISEASES, 2020, 67 (06) : 2365 - 2371
  • [26] Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know?
    Amauri Dalla Corte
    Carolina F. M. de Souza
    Maurício Anés
    Roberto Giugliani
    Child's Nervous System, 2017, 33 : 1073 - 1080
  • [27] Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know?
    Dalla Corte, Amauri
    de Souza, Carolina F. M.
    Anes, Mauricio
    Giugliani, Roberto
    CHILDS NERVOUS SYSTEM, 2017, 33 (07) : 1073 - 1080
  • [28] What do we know and what do we know about evolution?
    Vlchev, Boris
    SPISANIE NA B LGARSKOTO GEOLOGICHESKO DRUZHESTOV-REVIEW OF THE BULGARIAN GEOLOGICAL SOCIETY, 2020, 81 : 101 - 101
  • [29] Erratum to: What do we know? What do we need to know?
    Milena J. Henzlova
    W. Lane Duvall
    Journal of Nuclear Cardiology, 2017, 24 (1) : 255 - 255
  • [30] Presbyopia: What We Do Know and What We Do Not Know in 2022
    Grzybowski, Andrzej
    Gawecki, Maciej
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)